Silence Therapeutics (SLN) Current Deferred Revenue: 2019-2024
Historic Current Deferred Revenue for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to $306,000.
- Silence Therapeutics' Current Deferred Revenue rose 106.41% to $301,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $301,000, marking a year-over-year increase of 106.41%. This contributed to the annual value of $306,000 for FY2024, which is 95.34% down from last year.
- Silence Therapeutics' Current Deferred Revenue amounted to $306,000 in FY2024, which was down 95.34% from $6.6 million recorded in FY2023.
- In the past 5 years, Silence Therapeutics' Current Deferred Revenue registered a high of $21.9 million during FY2020, and its lowest value of $306,000 during FY2024.
- In the last 3 years, Silence Therapeutics' Current Deferred Revenue had a median value of $6.6 million in 2023 and averaged $5.9 million.
- As far as peak fluctuations go, Silence Therapeutics' Current Deferred Revenue surged by 591.67% in 2020, and later tumbled by 95.34% in 2024.
- Silence Therapeutics' Current Deferred Revenue (MRY) stood at $21.9 million in 2020, then plummeted by 73.30% to $5.8 million in 2021, then skyrocketed by 87.74% to $11.0 million in 2022, then plummeted by 40.10% to $6.6 million in 2023, then tumbled by 95.34% to $306,000 in 2024.
- Its Current Deferred Revenue stands at $306,000 for FY2024, versus $6.6 million for FY2023 and $11.0 million for FY2022.